A Phase Two Study of Two Doses of Leronlimab (Pro 140) in Combination with Trifluridine + Tipiracil (TAS-102) + Bevacizumab in Participants with CCR5+, Microsatellite Stable (MSS), Relapsed Refractory Metastatic Colorectal Cancer (mCRC)

This is an open label, randomized, two arm, multi-center study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and tipiracil + bevacizumab in patients with CCR5+, MSS, mCRC who have progressed on prior treatment before participating in the study. The main questions this study aims to answer are:
1. Can leronlimab, in combination with standard of care therapies trifluridine and tipiracil+ bevacizumab, increase the objective response rate in persons with CCR5+, MSS, mCRC who have progressed on prior treatment before participating in the study.
2. Is leronlimab safe and well tolerated in these subjects when used in combination with standard of care therapies trifluridine and tipiracil+ bevacizumab.

开始日期2025-02-01

申办/合作机构

CytoDyn, Inc.

[+1]

NCT05730673

/ Withdrawn临床2期

A Phase II Study of Leronlimab (PRO 140) in Combination With Regorafenib in Patients With CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC)

This is aPhase II Study of Leronlimab (PRO 140) in combination with Regorafenib in Patients with CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC)

开始日期2022-09-20

申办/合作机构

CytoDyn, Inc.

[+1]

NCT04901689

/ Suspended临床3期IIT

A Phase 3, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Leronlimab in Combination With Standard of Care for Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation

Leronlimab (PRO 140) is a humanized IgG4,k monoclonal antibody (mAb) that recognizes the C-C chemokine receptor type 5 (CCR5). Disruption of the C-C chemokine ligand 5 (CCL5)-CCR5 axis via leronlimab-mediated CCR5 blockade might prevent pulmonary trafficking of pro-inflammatory leukocytes and dampen pathogenic immune activation in coronavirus disease 2019 (COVID-19).
The purpose of the study is to assess the safety and efficacy of leronlimab plus standard of care in critically ill patients hospitalized with COVID-19 pneumonia who are requiring mechanical ventilation or extracorporeal oxigenation (ECMO).

开始日期2021-10-23

申办/合作机构

Hospital Israelita Albert Einstein

[+1]

100 项与 Leronlimab 相关的临床结果

登录后查看更多信息

100 项与 Leronlimab 相关的转化医学

登录后查看更多信息

100 项与 Leronlimab 相关的专利（医药）

登录后查看更多信息

项与 Leronlimab 相关的文献（医药）

2024-12-31·mAbs

FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques

Article

作者: Van Rompay, Koen K A ; Sacha, Jonah B ; Magnani, Diogo M ; Usachenko, Jodie L ; Schiffer, Celia A ; Shaqra, Ala M ; Zikos, Joanna ; Webb, Gabriela M ; Wu, Helen L ; Reed, Jason S ; Watanabe, Jennifer

Prenatal administration of monoclonal antibodies (mAbs) is a strategy that could be exploited to prevent viral infections during pregnancy and early life. To reach protective levels in fetuses, mAbs must be transported across the placenta, a selective barrier that actively and specifically promotes the transfer of antibodies (Abs) into the fetus through the neonatal Fc receptor (FcRn). Because FcRn also regulates Ab half-life, Fc mutations like the M428L/N434S, commonly known as LS mutations, and others have been developed to enhance binding affinity to FcRn and improve drug pharmacokinetics. We hypothesized that these FcRn-enhancing mutations could similarly affect the delivery of therapeutic Abs to the fetus. To test this hypothesis, we measured the transplacental transfer of leronlimab, an anti-CCR5 mAb, in clinical development for preventing HIV infections, using pregnant rhesus macaques to model in utero mAb transfer. We also generated a stabilized and FcRn-enhanced form of leronlimab, termed leronlimab-PLS. Leronlimab-PLS maintained higher levels within the maternal compartment while also reaching higher mAb levels in the fetus and newborn circulation. Further, a single dose of leronlimab-PLS led to complete CCR5 receptor occupancy in mothers and newborns for almost a month after birth. These findings support the optimization of FcRn interactions in mAb therapies designed for administration during pregnancy.

2024-11-01·Clinical Therapeutics

A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19

Article

作者: Sacha, Jonah B. ; Loftus, Richard ; Hansen, Scott G ; Sacha, Jonah B ; Sammartino, Daniel ; Ogbuagu, Onyema ; Yang, Otto O ; Lalezari, Jacob P ; Ojha, Sohita ; Yang, Otto O. ; Seethamraju, Harish ; Hansen, Scott G. ; Arman, Arvin Cyrus ; Lalezari, Jacob P. ; Mansour, Ali

PURPOSEEarly in the course of the SARS-CoV-2 pandemic it was hypothesised that host genetics played a role in the pathophysiology of COVID-19 including a suggestion that the CCR5-Δ32 mutation may be protective in SARS-CoV-2 infection. Leronlimab is an investigational CCR5-specific humanized IgG4 monoclonal antibody currently in development for HIV-1 infection. We aimed to explore the impact of leronlimab on the severity of disease symptoms among participants with mild-to-moderate COVID-19.METHODSThe TEMPEST trial was a randomized, double-blind, placebo-controlled study in participants with mild-to-moderate COVID-19. Participants were randomly assigned in a 2:1 ratio to receive subcutaneous leronlimab (700 mg) or placebo on days 0 and 7. The primary efficacy endpoint was assessed by change in total symptom score based on fever, myalgia, dyspnea, and cough, at end of treatment (day 14).FINDINGSOverall, 84 participants were randomized and treated with leronlimab (n = 56) or placebo (n = 28). No difference was observed in change in total symptom score (P = 0.8184) or other pre-specified secondary endpoints between treatments. However, in a post hoc analysis, 50.0% of participants treated with leronlimab demonstrated improvements from baseline in National Early Warning Score 2 (NEWS2) at day 14, compared with 20·8% of participants in the placebo group (post hoc; p = 0.0223). Among participants in this trial with mild-to-moderate COVID-19 adverse events rates were numerically but not statistically significantly lower in leronlimab participants (33.9%) compared with placebo participants (50.0%).IMPLICATIONSAt the time the TEMPEST trial was designed although CCR5 was known to be implicated in COVID-19 disease severity the exact pathophysiology of SARS-CoV-2 infection was poorly understood. Today it is well accepted that SARS-CoV-2 infection in asymptomatic-to-mild cases is primarily characterized by viral replication, with a heightened immune response, accompanied by diminished viral replication in moderate-to-severe disease and a peak in inflammatory responses with excessive production of pro-inflammatory cytokines in critical disease. It is therefore perhaps not surprising that no differences between treatments were observed in the primary endpoint or in pre-specified secondary endpoints among participants with mild-to-moderate COVID-19. However, the results of the exploratory post hoc analysis showing that participants in the leronlimab group had greater improvement in NEWS2 assessment compared to placebo provided a suggestion that leronlimab may be associated with a lower likelihood of people with mild-to-moderate COVID-19 progressing to more severe disease and needs to be confirmed in other appropriately designed clinical trials.CLINICALTRIALSgov number, NCT04343651 https://classic.CLINICALTRIALSgov/ct2/show/NCT04343651.

2024-02-07·Antimicrobial Agents and Chemotherapy

NorA efflux pump mediates Staphylococcus aureus response to Pseudomonas aeruginosa pyocyanin toxicity

Article

作者: Hooper, D. C. ; Lawton, B. G. ; Wang, Y. ; Truong-Bolduc, Q. C. ; Yonker, L. M.

ABSTRACT Endogenous transporters protect Staphylococcus aureus against antibiotics and also contribute to bacterial defense from environmental toxins. We evaluated the effect of overexpression of four efflux pumps, NorA, NorB, NorC, and Tet38, on S. aureus survival following exposure to pyocyanin (PYO) of Pseudomonas aeruginosa , using a well diffusion assay. We measured the PYO-created inhibition zone and found that only an overexpression of NorA reduced S. aureus susceptibility to pyocyanin killing. The MIC PYO of the NorA overexpressor increased threefold compared to that of wild-type RN6390 and was reduced 2.5-fold with reserpine, suggesting that increased NorA efflux caused PYO resistance. The PYO-created inhibition zone of a ΔnorA mutant was consistently larger than that of a plasmid-borne NorA overexpressor. PYO also produced a modest increase in norA expression (1.8-fold at 0.25 µg/mL PYO) that gradually decreased with increasing PYO concentrations. Well diffusion assays carried out using P. aeruginosa showed that ΔnorA mutant was less susceptible to killing by PYO-deficient mutants PA14 phzM and PA14 phzS than to killing by PA14. NorA overexpression led to reduced killing by all tested P. aeruginosa . We evaluated the NorA–PYO interaction using a collection of 22 clinical isolates from adult and pediatric cystic fibrosis (CF) patients, which included both S. aureus (CF-SA) and P. aeruginosa (CF-PA). We found that when isolated alone, CF-PA and CF-SA expressed varying levels of PYO and norA transcripts, but all four CF-PA/CF-SA pairs isolated concurrently from CF patients produced a low level of PYO and low norA transcript levels, respectively, suggesting a partial adaptation of the two bacteria in circumstances of persistent co-colonization.

106

项与 Leronlimab 相关的新闻（医药）

2025-03-18

·GlobeNewswire-Health Care

March 2025 Letter to Shareholders

VANCOUVER, Washington, March 18, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As envisioned, 2025 is unfolding to be an exciting year for CytoDyn Inc. (“CytoDyn” or the “Company”). On February 24, 2025, the Company announced increased survival rates in patients with metastatic Triple-Negative Breast Cancer (“mTNBC”) who were treated with leronlimab in prior CytoDyn-sponsored studies. The impressive survival observations at 12, 24, and 36 months in patients who previously failed treatment in the metastatic or locally advanced setting indicate leronlimab could play a significant role as a paradigm-shifting therapeutic in oncology. Of particular interest, we identified a subgroup of these patients who remain alive and well today and currently identify as cancer-free. This is only the beginning of the Company’s 2025 oncology story. We are eager to provide updates in the coming months as they are available to share. There is still much work to be done, but I am encouraged by what is on the near horizon. I’d like to offer a word of deep gratitude to the CytoDyn team and the key opinion leaders (“KOLs”) who worked so diligently these last months to bring these data together. I would also like to reiterate my appreciation for you – the shareholders. Our business priorities are (i) getting leronlimab to patients in need; and (ii) generating value for our dedicated shareholders. As a long-time supporter of the company and now CEO, I believe investors deserve clear and direct updates as it relates to milestones, regulatory process, and finances. We will continue to incorporate this principle into our messaging as we move forward, presenting a clear picture of where we stand in the development pipeline and celebrating major milestones together. Looking ahead, we are excited to share more about the clarity forming around the putative mechanism of action of leronlimab in solid tumors, as well continued updates relating to the Colorectal Cancer (“CRC”) trial, as further described below. In terms of the regulatory process, I am confident that our collaborative relationship with the FDA has placed us on a positive trajectory. To accelerate progress in oncology where feasible, we’re establishing an oncology advisory board to ensure we are exploring the fastest and most responsible pathway(s) forward. We will continue to look for opportunities to solicit feedback regarding our development process from both KOLs and the FDA. Maintaining strong relationships and credibility with the FDA and industry partners remains a top priority as we chart our future course. The Company continues to be on track financially and we forecast sufficient cash and drug supply on hand to advance our clinical priorities in 2025. As we approach key milestones and announcements in the coming months, we’ll evaluate opportunities to raise additional funds at optimal times and through methods that best serve the Company and its shareholders. We believe leronlimab has already established the potential for tremendous value in the clinic, and in the coming months we look forward to sharing the basis for that conclusion. In sum, the developments in oncology have set the stage for 2025 to be a benchmark year for CytoDyn. This is no longer a platform drug in search of an indication; we now have compelling data to support a role for leronlimab in solid-tumor oncology and are executing on that vision. With Gratitude, Jacob Lalezari, MDCEO Oncology – March 2025 Update The Company continues to prioritize oncology in 2025, as we believe this indication holds the highest potential and shortest timeline for return on investment in the form of a partnership or drug approval. The exciting survival outcomes announced in February 2025 provide early clinical evidence of leronlimab’s potential impact across the field of solid-tumor oncology. As previously announced, we’ve submitted our findings as an abstract to the European Society for Medical Oncology meeting in Munich, Germany in May 2025. We are eager to share additional insights into the apparent mechanism behind the survival outcomes and will do so once appropriate and in compliance with pre-conference publication and announcement allowances. In the meantime, CytoDyn has initiated a follow-up protocol so we can continue to monitor the surviving patients into the future. The CytoDyn/Syneos study teams have now approved eight clinical sites and counting to participate in CytoDyn’s Phase II study of patients with CRC and refractory disease. These clinical sites will include a mix of both large community practices as well as academic centers which all have well-established track records of superior work and high enrollment. With our clinical trial agreements in place and study initiation visits about to start, we expect screening of patients into the CRC study to commence shortly. As previously mentioned, Dr. Ben Weinberg from Georgetown University and the MedStar Health Alliance will be the lead Principal Investigator for the CRC study. Per the FDA’s request, the first five patients enrolled will receive 350 mg of leronlimab SQ once/week in combination with TAS-102 and bevacizumab. After a preliminary safety review by the Data and Safety Monitoring Board (“DSMB”), subsequent patients will be randomized to 350 or 700 mg of weekly leronlimab along with the same background regimen. The DSMB will perform a second safety review after the first 20 patients have completed at least 1 cycle of therapy and can then recommend restricting further enrollment to a single dose level, if deemed appropriate. For additional information, the CRC study protocol is posted on the NCI Clinical Trials website, and can be viewed here. In concert with the observation of prolonged survival in patients with mTNBC described above, CytoDyn remains focused on expeditiously resuming our clinical development in this indication. Two previously announced preclinical studies in TNBC that will identify treatment strategies to optimize the design of future studies are now underway. A third study has begun to further examine the apparent mechanism behind the observed increase in survival as compared to existing treatment paths. In the meantime, we will continue discussions with KOLs about the possibility of initiating a follow-up study in patients with mTNBC on an abbreviated timeline, based on currently available data. The Company also continues to explore the possible use of leronlimab in the treatment of glioblastoma multiforme (“GBM”). A preclinical study at the Albert Einstein College of Medicine sequencing temozolomide and leronlimab is now underway. CytoDyn is also in discussions with several KOLs in neuro-oncology about the possibility of initiating a pilot study in patients with GBM, also based on currently available data. Inflammation – March 2025 Update As previously announced, CytoDyn applied to the NIH/RECOVER-TLC group for the inclusion of leronlimab in their next round of Long Covid treatment studies. The shifting policy landscape in the United States has created some uncertainty around government-sponsored funding of research, but we have been informed by a member of the RECOVER team that their review process has resumed, and we expect a decision soon. In addition, the protocol for a pilot study of leronlimab in the treatment of patients with mild to moderate Alzheimer’s Disease (“AD”) is now finalized. The study will take place at Cornell Medical Center in New York and will evaluate a neuroradiology endpoint that should provide a clear signal of leronlimab’s potential role in treating AD. The study is fully funded, and our colleagues at Cornell are engaged to move the project forward through Cornell’s institutional review process and FDA submission. A new collaborator, Dr. Tom Carmichael, Professor and Chair of Neurology at the University of California, Los Angeles, has published important preclinical observations demonstrating how a small molecule CCR5 inhibitor can expedite recovery following a cerebrovascular accident (“CVA” or “stroke”). CytoDyn is working with Dr. Carmichael and Dr. Kate Schunke at the University of Hawaii to conduct a preclinical study of stroke in transgenic mice that express human CCR5. We are excited by this initiative, given our view that there is an unmet need for innovative and effective treatment paths for patients in this category, and our belief that the market for therapies to treat stroke and/or traumatic brain injury could grow significantly over the next several decades. Dr. Carmichael will also be advising on the pilot study of AD to be initiated at Cornell Medical Center in New York. As announced via press release on February 6, 2025, the final results from SMC Laboratories (“SMC”) indicated statistically significant reversal of liver fibrosis (p< 0.01) in all 3 studies conducted at SMC. Importantly, the reversal of fibrosis appears to be independent of the mechanism of liver insult, as the effect was seen in both metabolic-dysfunction associated steatohepatitis (“MASH”) and CCL4 models of liver injury. To call attention to a key point of clarification, the final results at SMC did not confirm a significant effect of leronlimab on fat accumulation in the liver in the MASH model. Given this observation, we will pause development efforts related to MASH in the near term. Instead, we are continuing discussions with potential partners who have expressed interest in funding studies of leronlimab in the treatment of patients with organ fibrosis to build on the promising findings listed above. Other – March 2025 Update As previously announced, CytoDyn is partnering with the American Foundation for AIDS Research (“amfAR”) to sponsor an HIV cure study called LATCH (Leronlimab in Allogenic stem cell Transplant to Cure HIV). The clinical teams at Oregon Health and Sciences University and the University of Washington remain confident in the chances of success of their LATCH protocol and we look forward to the launch of this program in 2025. CytoDyn continues to prioritize the publication of our clinical data. The exciting observation of improved survival in patients with mTNBC treated with leronlimab has naturally prompted us to reframe the focus of our oncology manuscripts. Submission of these oncology manuscripts for peer review is a top publication priority. Additional ongoing publication efforts include: The manuscript for our CD02 Phase 3 study in patients with multi-drug-resistant HIV was recently published by the Journal of Acquired Immune Deficiency Syndromes and has been posted to our website.The manuscripts for the CD12 Acute Covid and MASH clinical studies are in final preparation for submission.A manuscript summarizing the results of treatment with leronlimab on liver fibrosis from SMC is in preparation.As previously announced, CytoDyn is preparing a manuscript summarizing the integrated safety data from the almost 1,600 patients who have already received leronlimab. The final draft of that safety summary will be completed shortly. Note Regarding Forward-Looking Statements This letter contains forward-looking statements relating to, among other things, clinical drug development and research strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2024, including the section captioned “Forward-Looking Statements,” and in Part I, Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statements as a result of new information or future events or developments other than as required by law. Media Contacts CytoDynRiyaz LalaniGagnier CommunicationsCytoDyn@gagnierfc.com

临床2期临床3期

2025-03-06

·小药说药

GPCR：从基础科学到临床转化的全景透视

-01- 导读 GPCR(G Protein-Coupled Receptor)，即G蛋白偶联受体，是哺乳动物基因组中最大的膜蛋白家族，广泛分布于中枢神经系统、免疫系统、心血管、视网膜等器官和组织，参与机体的发育和正常的功能行使。而如果与其相关的细胞内通路调节发生异常，或者外源病原物以之为受体攻击机体细胞，则会导致一系列疾病的发生。因此，GPCR被视为重要的药物开发靶点，GPCR的药物研发具有非常重要的价值。 -02- GPCR简介 G蛋白偶联受体（GPCR）是真核生物中最大的膜蛋白家族，具有七次跨膜α螺旋结构。其N端和三个胞外环参与配体结合，而C端和胞内环（尤其是第三个环）介导下游信号传导。GPCR通过两种主要途径传递信号：一是依赖G蛋白（如Gs、Gi/o、Gq/11等），激活后产生第二信使（如cAMP、Ca²⁺）；二是非依赖途径（如β-arrestin介导的Src/激酶活化）。针对GPCR超家族的成员，有多种不同的分类方法，比较流行的有两种：一是A-F分类系统，面向所有生物体内的GPCR蛋白；另一种是根据序列相似性和功能相似性，将GPCR分为Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, Secretin等5类（缩写为GRAFS），绝大部分人源GPCR可被归类其中。 Rhodopsin家族（Class A）：最大类别，N端较短，配体直接结合跨膜区或通过胞外环间接作用，包括胺类（如多巴胺、组胺受体）、多肽类（如内皮素受体）等。该家族可被进一步分为α、β、γ和δ亚类。α亚类的成员包含多种重要的胺类和小分子化合物的受体，包括组胺受体、多巴胺受体、大麻素受体等。β亚类包含多种多肽受体，如内皮素受体、催产素受体等。γ亚类中较受关注的一类受体是趋化因子受体家族，其他的成员包括一些趋化素受体、神经肽受体等。δ亚类包括一些糖蛋白受体和嗅觉相关的受体等。总体来讲，Rhodopsin受体家族成员比较复杂，很难基于结构、功能、表达分布等单一特点进行分类。 Secretin家族（Class B1）：胞外区域较大，成员为多肽激素受体（如分泌素受体）。 Adhesion家族（Class B2）：结构与Class B1类似，但多数成员的天然配体尚未明确。 Glutamate家族（Class C）：具有较大的N端二聚体结构，成员包括代谢型谷氨酸受体、GABA受体、钙敏感受体及味觉受体（如甜/鲜味受体TAS1R）。 Frizzled/Taste2家族（Class F）：分为两个亚类，Frizzled/Smoothened：结合Wnt蛋白或通过Hedgehog通路传递信号；Taste2：苦味受体及一些孤儿受体。 GPCR激活后通过构象变化（如磷酸化）招募β-arrestin，调控受体内吞或信号终止。此外，GPCR的亚细胞定位（如核膜）可影响其信号特异性。药物开发中，约370个GPCR为潜在靶点，现有药物以调节G蛋白或β-arrestin通路为主。 -03- GPCR的信号通路 G蛋白偶联受体（GPCR）是人体最大的跨膜受体家族，通过感知光、激素、神经递质等信号，调控约80%的生理过程。其信号传递具有高度动态性和复杂性，核心路径可分为G蛋白依赖性通路和β-arrestin依赖性通路，同时受多种调控机制影响。 G蛋白依赖性通路 GPCR通过与G蛋白相互作用来传递信号。G蛋白是由三个亚基组成的异源三聚体：Gα、Gβ和Gγ。当GPCR被配体激活时，会发生构象变化，促使G蛋白α亚基的GDP被GTP取代，进而激活与其偶联的G蛋白。 Gs型：激活腺苷酸环化酶（AC），升高cAMP水平，激活PKA（如肾上腺素受体调控代谢）。 Gi/o型：抑制AC，降低cAMP水平（如阿片受体介导镇痛）。 Gq/11型：激活磷脂酶Cβ（PLCβ），水解PIP₂生成IP₃和DAG，分别触发钙离子释放和PKC活化（如血管紧张素受体调控血压）。 G12/13型：激活RhoGEF，调控细胞骨架重塑（如趋化因子受体驱动细胞迁移）。 β-arrestin依赖性通路 β-arrestin是GPCR信号通路中的重要调节因子，GPCR被G蛋白偶联受体激酶（GRK）磷酸化后，招募β-arrestin结合，介导受体内吞和脱敏，终止G蛋白信号。此外，还激活非经典通路如ERK、JNK激酶级联反应（如CXCR4受体促进肿瘤转移）以及与AP2等衔接蛋白结合，调控膜运输和信号复合物组装。 -04- GPCR与疾病的关系 GPCR家族在人体内分布广泛，功能复杂，因此与多种疾病的发生和进展过程有所关联，或在其中扮演重要的角色。根据截止到目前的较为清楚的研究，GPCR涉及到的疾病主要分为3大类：癌症、炎症和心血管/代谢疾病。 GPCR与癌症研究表明，GPCR家族的多种成员参与了各类癌症的发生和进展。激素受体类的GPCR参与了某些激素依赖的癌症。有些蛋白酶激活受体如PAR1，在MMP-1的催化下活化并激活下游信号通路，促进癌细胞的侵袭和恶化。有些趋化因子受体，如CXCR2、CXCR4，在骨髓瘤、淋巴瘤细胞中高表达，也可能高表达在如胰腺癌等实体瘤细胞上，参与细胞的迁移、血管生成等。 GPCR与炎症趋化因子受体家族主要表达在免疫系统各类细胞上，炎症反应就是由免疫细胞上的趋化因子受体受趋化因子激活后介导免疫细胞发挥宿主免疫功能而产生的一类病理现象。如CXCR1、CXCR2主要表达于中性粒细胞上，当机体某处发生感染或出现损伤时，中性粒细胞会在相应趋化因子（CXCL1、CXCL2、CXCL8）的趋化下向病灶迁移，到达病灶后释放炎症因子，从而产生局部的炎症反应。 GPCR与心血管/代谢疾病与心血管疾病相关的GPCR成员主要分布于ClassA家族的α亚类，如血管紧张素系统（RAAS）中的AT1R、AT2R以及Mas-R。AT1R受体激活引起血管收缩，细胞增殖迁移、炎症纤维化、心肌再塑和肥厚、钠水潴留和ROS生成等等；而Mas受体激活主导血管舒张、抑制细胞增殖迁移、抗炎症纤维化、抗凝、促EDRF、NO生成、抑制心肌肥厚和生长等等，两者具有相互拮抗的作用，共同维持人体的自稳态。与代谢疾病相关的GPCR成员主要是分布于ClassA家族中的脂肪酸受体，比如GPR120、GPR41和GPR43等，以及ClassB家族中的Secretin受体家族，包括GLP-1R和GCGR等。胰高血糖素样肽1（GLP-1）通过激活GLP-1R，提高胰岛β细胞的胰岛素分泌水平，从而控制血糖；胰高血糖素（GCG）通过与其受体GCGR结合而被激活，增强肝糖原降解，并调节葡萄糖的从头合成途径，抵抗胰岛素的降血糖作用，从而升高血糖。除了这3类疾病主要的疾病之外，还有其他疾病被证明与GPCR相关，如：CCR5参与HIV向T细胞的入侵，是治疗艾滋病的一个重要靶点；如降钙素相关基因肽受体CGRPR和其配体CGRP表达于三叉神经元区域，两者的相互作用所激活的下游信号通路被证明与偏头痛相关。 -05- GPCR药物开发现状目前在北美（美国和加拿大）、欧洲、亚洲（日本、韩国和印度）和澳大利亚的市场上共有516种针对GPCR的不同药物在销售。这些GPCR靶向药物占所有批准药物的约36%。在过去的5年里（自2019年以来），有37种针对GPCR的药物获得了新的批准，其中包括7种首次批准的受体：GIPR、GPRC5D、C5A1、神经激肽-3（NK3）和黑皮质素受体3、4和5（MC3/4/5）。最近批准的是KarXT（Cobenfy），这是一种由M1/M4毒蕈碱乙酰胆碱受体选择性激动剂xanomeline和外周毒蕈碱拮抗剂曲司皮铵联合使用的药物，是精神分裂症的治疗药物。目前共有337种靶向GPCR的药物正在临床试验中，其中172种是新药，165种是正在重新利用的药物。在新的药物中，有51、76和45种分别进入了I、II和III期临床。因此，预计未来几年将有相当多的GPCR药物获得批准。 2023年前50大畅销药物中有5种GPCR靶向产品。其中，产品Entresto（sacubitril/缬沙坦）应用于心力衰竭和高血压。其他四种产品分布在代谢疾病领域的适应症：包括2型糖尿病（semaglutide、dulaglutide和tirzepatide）和肥胖症（semagluide）。tirzepatide也于2023年11月被批准用于治疗肥胖症。目前只有两种批准的GPCR靶向单克隆抗体，分别是靶向CCR4和CGRP1型受体的mogamulizumab和erenumab。另一种单克隆抗体正处于临床开发的后期阶段，即针对CCR5的leronlimab（或PRO140），现已达到预注册。目前还有多个GPCR的单克隆抗体处于临床1期或2期的开发阶段。值得注意的是，所有这些靶点都有大的肽配体。-06- GPCR药物的未来发展趋势 GPCR药物开发近年来呈现多维度创新趋势，但仍面临结构生物学限制和选择性挑战。以下是核心进展与方向：结构生物学驱动药物发现过去5年上市的GPCR药物均基于已解析的受体结构开发，凸显结构信息的关键作用。随着X射线晶体学和冷冻电镜技术进步，变构位点的发现为药物设计开辟新路径，例如靶向受体-脂膜界面变构位点的小分子可克服传统正构药物选择性不足的问题。目前已有18种GPCR与变构分子的共晶结构被解析，为精准设计提供模板。从正构位点到变构调控的范式转变约95%已上市GPCR药物靶向正构位点，但该区域在同类受体中高度保守，导致药物交叉激活引发毒副作用。变构调节剂通过结合受体跨膜区或脂膜界面等非保守区域，实现亚型特异性调控。例如，钙感知受体（CaSR）变构调节剂cinacalcet通过“天花板效应”限制药效峰值，显著提高安全性。此外，变构位点不与内源配体竞争，可保留天然信号时空特性，适用于需精细调节的疾病（如神经系统疾病）。 GPCR抗体的崛起抗体药物凭借长半衰期、高选择性和外周分布特性，成为小分子的重要补充。例如，针对外周表达的GPCR开发抗体可规避血脑屏障，减少中枢副作用。目前已有2款GPCR抗体药物上市，临床阶段项目数量显著增加。靶向受体复合物的新维度GPCR常与受体相关蛋白形成功能复合物，其信号特性与单体受体不同。例如，多巴胺D2受体与腺苷A2A受体异源二聚化可改变配体响应，为帕金森病治疗提供新靶点。此类复合物的组织特异性表达（如特定细胞类型中GPCR与辅助蛋白的共定位）使药物可精准调节病理信号通路，减少脱靶效应。此外，开发偏向性配体以调控特定信号通路、利用AI预测变构位点结合模式、探索孤儿GPCR的变构成药潜力。这些突破将推动GPCR药物向更高选择性和更低毒性的方向发展。 -06- 结语 GPCR药物开发的历史，是一部人类解码生命信号、攻克疾病的壮丽史诗。从阿司匹林抗炎止痛的偶然发现，到GLP-1受体激动剂改写糖尿病治疗格局，再到靶向CGRP受体单抗开创偏头痛预防新时代，GPCR药物始终站在医学革命的前沿。目前，针对GPCR的治疗性药物的研发管线和临床试验正在不断扩大。近年来，随着我们对GPCR生物学方面的不断深入研究，可以预见，GPCR作为生命科学的“百年常青树”，将持续解锁细胞信号调控的终极密码。当科学与技术跨越学科的藩篱，人类终将实现从“调控疾病”到“重塑健康”的终极梦想。参考文献： 1. A review of antibody-based therapeutics targeting G protein-coupled receptors: an update. Catherine J Hutchings. Expert Opin Biol Ther. 2020 Aug;20(8):925-935. 2. Targeting receptor complexes: a new dimension in drug discovery.Nat Rev Drug Discov. 2020 Nov 11. 3. New Binding Sites, New Opportunities for GPCR DrugDiscovery. Trends Biochem Sci. 2019 Apr;44(4):312-330. 4. GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov.2025 Mar 3. 公众号内回复“ADC”或扫描下方图片中的二维码免费下载《抗体偶联药物：从基础到临床》的PDF格式电子书！公众号已建立“小药说药专业交流群”微信行业交流群以及读者交流群，扫描下方小编二维码加入，入行业群请主动告知姓名、工作单位和职务。

细胞疗法孤儿药

2025-01-30

·PRNewswire

Metabolic Dysfunction-Associated Steatohepatitis Market to Register Stunning Growth at a CAGR of 17.9% in the US by 2034 | DelveInsight

The MASH treatment landscape is evolving rapidly, driven by a diverse array of therapeutic classes, each with unique mechanisms and potential impacts. The forecast period reveals significant shifts and emerging trends that will shape future market dynamics. LAS VEGAS, Jan. 30, 2025 /PRNewswire/ -- DelveInsight's Metabolic Dysfunction-Associated Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, MASH emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Metabolic Dysfunction-Associated Steatohepatitis Market Report According to DelveInsight's analysis, the market size for MASH was found to be USD 2.1 billion in the 7MM in 2023. In 2023, there were an estimated 42 million prevalent cases of MASH in the 7MM. Out of these, a total of ~15 million cases were diagnosed, and this number is projected to increase by the end of 2034 in the 7MM. Leading MASH companies such as Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Akero Therapeutics, 89bio, Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics, Lipocine, Viking Therapeutics, Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai), Hepion Pharmaceuticals, Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences, Ionis Pharmaceuticals, Corcept Therapeutics, and others are developing novel MASH drugs that can be available in the MASH market in the coming years. The promising MASH therapies in the pipeline include Lanifibranor (IVA337), Semaglutide, Azemiglitazone (MSDC-0602K), Efruxifermin (EFX), BIO89-100 (Pegozafermin), Survodutide (BI 456906), GR-MD-02 (Belapectin), LPCN1144, VK2809, Tirzepatide, BOS-580, Ervogastat (PF-06865571) + Clesacostat (PF-05221304), HTD1801, Leronlimab (PRO 140), Efinopegdutide, HPG1860, Rencofilstat (CRV431), EYP001 (Vonafexor), Semaglutide/Cilofexor/Firsocostat, PXL065, Saroglitazar Magnesium, Denifanstat (TVB-2640), ION224, Miricorilant (CORT118335), and others. In March 2024, Madrigal Pharmaceuticals' groundbreaking product, REZDIFFRA (resmetirom), a once-daily, oral THR-ß agonist, received accelerated endorsement from the US FDA based on results from the Phase III MAESTRO-NASH trial. This approval marks a significant stride in the medical landscape, as REZDIFFRA becomes the inaugural and sole FDA-sanctioned therapy for adults afflicted with non-cirrhotic MASH, accompanied by moderate to advanced liver scarring (fibrosis) corresponding to stages F2–F3 fibrosis. Discover which therapies are expected to grab the major MASH market share @ Metabolic Dysfunction-Associated Steatohepatitis Market Report Metabolic Dysfunction-Associated Steatohepatitis Overview Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that stems from metabolic dysfunction, often linked to obesity, diabetes, and other conditions of metabolic syndrome. MASH is characterized by the accumulation of fat in liver cells, accompanied by inflammation and liver cell injury, which can progress to fibrosis, cirrhosis, or even liver cancer. The primary drivers of MASH include insulin resistance, obesity, type 2 diabetes, and dyslipidemia. Genetic predisposition and a sedentary lifestyle also play significant roles. Environmental factors, such as a poor diet high in sugars and fats, exacerbate the condition. MASH is often asymptomatic in its early stages. When symptoms occur, they can include fatigue, vague abdominal discomfort, or pain in the upper right quadrant. In advanced stages, signs of liver dysfunction such as jaundice, swelling of the abdomen or legs, and confusion may arise. Diagnosis involves a combination of clinical history, physical examination, and diagnostic tests. Blood tests measuring liver enzymes (ALT, AST) often indicate liver inflammation. Imaging techniques like ultrasound, MRI, or FibroScan can identify liver fat and fibrosis. In some cases, a liver biopsy is required to confirm the diagnosis and assess disease severity. Metabolic Dysfunction-Associated Steatohepatitis Epidemiology Segmentation The MASH epidemiology section provides insights into the historical and current MASH patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The MASH market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Prevalent Cases of MASH Diagnosed Prevalent Cases of MASH Gender-specific Diagnosed Prevalent Cases of MASH Severity-specific Diagnosed Prevalent Cases of MASH Metabolic Dysfunction-Associated Steatohepatitis Treatment Market The approval of REZDIFFRA (resmetirom) in March 2024 represents a pivotal achievement in medical innovation, transforming the treatment landscape for MASH disease. This groundbreaking therapy addresses the root causes of MASH, offering renewed hope to patients grappling with this challenging condition. Clinical trials have shown impressive results, with REZDIFFRA effectively reducing symptoms like inflammation and fibrosis, enhancing liver function, and improving patients' quality of life. By providing healthcare professionals with a robust treatment option, this approval addresses a critical unmet need and has the potential to significantly alleviate the complications linked to advanced liver disease. The prevalence of MASLD is strongly linked to type 2 diabetes mellitus and obesity, particularly in individuals with a higher body mass index. However, MASLD occurrence is reduced in T2DM patients receiving treatments such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, GLP-1 receptor agonists, and insulin. Vitamin E, with its antioxidant properties, is regarded as a first-line pharmacological option for managing MASH, especially when dietary and lifestyle interventions are insufficient. Antifibrotic agents can help prevent the progression of liver fibrosis and MASLD into fibrotic MASH. The role of pioglitazone, an anti-diabetic medication, in improving MASH histology in T2DM patients is well-documented, but concerns remain regarding potential side effects like weight gain, fluid retention, cancer risk, and bone fractures. Additional therapeutic targets for MASLD and MASH include G protein-coupled receptors (GPCRs), estrogen-related receptor alpha (ERRα), bone morphogenetic proteins (BMPs), and KLFs. Bariatric surgery, or weight loss surgery, is the most effective intervention for treating obesity and diabetes, as it reduces food absorption while influencing gut hormone secretion and metabolic function. To know more about MASH treatment guidelines, visit @ Metabolic Dysfunction-Associated Steatohepatitis Management Metabolic Dysfunction-Associated Steatohepatitis Pipeline Therapies and Key Companies Lanifibranor (IVA337): Inventiva Pharma Semaglutide: Novo Nordisk A/S Azemiglitazone (MSDC-0602K): Cirius Therapeutics Efruxifermin (EFX): Akero Therapeutics BIO89-100 (Pegozafermin): 89bio Survodutide (BI 456906): Boehringer Ingelheim/Zealand Pharma GR-MD-02 (Belapectin): Galectin Therapeutics LPCN1144: Lipocine VK2809: Viking Therapeutics Tirzepatide: Eli Lilly and Company BOS-580: Boston Pharmaceuticals Ervogastat (PF-06865571) + Clesacostat (PF-05221304): Pfizer HTD1801: HighTide Biopharma Leronlimab (PRO 140): CytoDyn Efinopegdutide: Merck & Co./Hanmi Pharmaceutical HPG1860: Hepagene (Shanghai) Rencofilstat (CRV431): Hepion Pharmaceuticals EYP001 (Vonafexor): Enyo Pharmaceuticals Semaglutide/ Cilofexor/ Firsocostat: Gilead Sciences PXL065: Poxel SA Saroglitazar Magnesium: Zydus Therapeutics Denifanstat (TVB-2640): Sagimet Biosciences ION224: Ionis Pharmaceuticals Miricorilant (CORT118335): Corcept Therapeutics Discover more about MASH drugs in development @ Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials Metabolic Dysfunction-Associated Steatohepatitis Market Dynamics The MASH market dynamics are expected to change in the coming years. Growing research activities and multiple clinical trials for MASH, driven by the rapid surge in its prevalence due to rising obesity and type 2 diabetes rates, highlight an active drug development pipeline and an expanding market size. The large pool of patients and lucrative growth opportunities present attractive prospects for key players, further supported by ongoing preclinical studies aimed at advancing imaging techniques for MASH diagnosis, potentially eliminating the need for invasive biopsy-based histopathological confirmation. Furthermore, potential therapies are being investigated for the treatment of MASH, and it is safe to predict that the treatment space will significantly impact the MASH market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the MASH market in the 7MM. However, several factors may impede the growth of the MASH market. Lack of awareness and negligence in the early stages of MASH by physicians often lead to disease progression, culminating in irreversible damage where liver transplantation becomes the only viable option. Diagnosing advanced MASH typically requires procedures like liver biopsy, which are costly, invasive, and risky. Regulatory challenges also pose hurdles, as the FDA mandates achieving one MASH endpoint for approval, while the EMA's draft guidance requires efficacy in both endpoints, potentially delaying first-mover approvals in major European markets. Additionally, access to expensive MASH treatments may be limited in certain regions, further hindering patient adoption. Moreover, MASH treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, MASH market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact MASH market growth. Scope of the Metabolic Dysfunction-Associated Steatohepatitis Market Report Therapeutic Assessment: Metabolic Dysfunction-Associated Steatohepatitis current marketed and emerging therapies Metabolic Dysfunction-Associated Steatohepatitis Market Dynamics: Key Market Forecast Assumptions of Emerging Metabolic Dysfunction-Associated Steatohepatitis Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Metabolic Dysfunction-Associated Steatohepatitis Market Access and Reimbursement Download the report to understand which factors are driving MASH market trends @ Metabolic Dysfunction-Associated Steatohepatitis Market Trends Table of Contents Related Reports Non-Alcoholic Steatohepatitis Epidemiology Forecast Non-Alcoholic Steatohepatitis Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted NASH epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. Nonalcoholic Steatohepatitis Pipeline Nonalcoholic Steatohepatitis Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nonalcoholic steatohepatitis companies, including Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Inventiva, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, 89bio, Inc., Eccogene, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Arrowhead Pharma, LG Chem, Redx Pharma, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Chemomab Therapeutics, NuSirt Biopharma, HK inno. N, Aligos Therapeutics, Altimmune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, Sunshine Lake Pharma, GSK plc., Future Medicine, Gilead Sciences, ENYO Pharma, Histogen, among others. Non-Alcoholic Fatty Liver Disease Market Non-Alcoholic Fatty Liver Disease Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key NAFLD companies, including MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc. , among others. Non-Alcoholic Fatty Liver Disease Pipeline Non-Alcoholic Fatty Liver Disease Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NAFLD companies, including BeiGene, Inventiva Pharma, Cirius Therapeutics, Madrigal Pharma, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Dr. Falk Pharma GmbH, Sagimet Biosciences, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Afimmune, Poxel SA, AngioLab, Pfizer, Oramed Pharmaceuticals, Can Fite Biopharma, MediciNova, Metacrine, Inc., Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma, Chemomab Therapeutics, NuSirt Biopharma, HK inno.N, Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Enanta Pharmaceuticals, Cascade Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期

100 项与 Leronlimab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11399	Leronlimab	-	DB05941

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HIV感染	临床3期	美国	CytoDyn, Inc.	2021-11-01
新型冠状病毒感染	临床3期	美国	CytoDyn, Inc.	2020-08-05
HIV感染	临床2期	美国	CytoDyn, Inc.	2021-11-01
急性移植物抗宿主病	临床2期	美国	CytoDyn, Inc.	2017-05-14
急性髓性白血病	临床2期	美国	CytoDyn, Inc.	2017-05-14
骨髓增生异常综合征	临床2期	美国	CytoDyn, Inc.	2017-05-14
HIV感染	药物发现	美国	CytoDyn, Inc.	2021-11-01
非酒精性脂肪性肝炎	药物发现	美国	CytoDyn, Inc.	2020-12-01
实体瘤	药物发现	美国	CytoDyn, Inc.	2020-05-01
三阴性乳腺癌	药物发现	美国	CytoDyn, Inc.	2019-04-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04678830 (CTgov)	临床2期	新冠肺炎后遗症	56	Leronlimab (700mg) (700mg Leronlimab)	膚廠製壓齋製窪構糧憲(壓積壓艱壓淵築築簾襯) = 選膚積醖繭製遞鏇壓窪積窪鹽壓顧願顧製顧鏇 (鑰遞遞衊鬱鏇醖衊衊鬱, 網糧餘廠繭願簾襯製願 ~ 蓋膚顧襯窪觸衊糧夢憲) 更多	-	2024-04-11
				Placebos (Placebo)	膚廠製壓齋製窪構糧憲(壓積壓艱壓淵築築簾襯) = 鹹醖夢簾鏇齋觸廠膚顧積窪鹽壓顧願顧製顧鏇 (鑰遞遞衊鬱鏇醖衊衊鬱, 觸夢顧蓋選簾選簾製膚 ~ 鏇築糧醖築憲憲範壓選) 更多
NCT02737306 (GVHD, CTgov)	临床2期	急性髓性白血病 \| 急性移植物抗宿主病 \| 骨髓增生异常综合征	11	Placebo	鏇醖醖餘壓鑰鏇選衊鏇(選膚膚鏇膚窪膚範鹹襯) = 觸窪構窪鑰積鏇積積襯鹹繭築醖齋壓夢鹹鏇淵 (繭積鏇憲願衊網顧選鬱, 鹽鏇鹽觸觸觸鬱夢網鏇 ~ 積鏇鏇構鹹獵窪淵遞醖) 更多	-	2024-03-12
NCT02175680 (CTgov)	临床2期	HIV感染	43	Historical data+PRO 140	積衊鹹遞齋築構觸選範(齋憲獵糧築襯觸醖獵構) = 蓋選繭餘簾構鏇製簾糧鏇遞觸獵鹽鏇鹹膚獵壓 (製壓鏇餘糧夢淵蓋積鬱, 壓蓋窪膚蓋齋繭獵淵夢 ~ 範鹹願廠製觸願範鑰衊) 更多	-	2023-04-14
NCT00110591 (CTgov)	临床1期	HIV感染	20	PRO 140 (Placebo)	鏇範顧蓋鑰壓膚築糧築(遞衊顧構衊顧餘繭選憲) = 觸鬱範顧廠膚夢觸網夢憲構艱鹽餘餘範艱製糧 (願鹽餘鑰餘壓壓繭夢觸, 餘遞廠遞鬱廠觸觸淵製 ~ 遞遞餘襯壓衊築艱願糧) 更多	-	2023-03-14
				PRO 140 (PRO 140 Dose 1)	鏇範顧蓋鑰壓膚築糧築(遞衊顧構衊顧餘繭選憲) = 構簾齋築築鬱衊鏇選廠憲構艱鹽餘餘範艱製糧 (願鹽餘鑰餘壓壓繭夢觸, 鑰獵繭構鬱簾壓糧鏇衊 ~ 遞淵觸窪簾襯遞廠糧醖) 更多
NCT04521114 (NASH, CTgov)	临床2期	非酒精性脂肪性肝炎	87	leronlimab 700 mg (Leronlimab 700 mg)	繭艱製構憲醖積夢窪餘(網簾鹹積獵鏇鹽積鏇壓) = 遞鹹積艱獵顧醖齋範鹽糧選鑰遞鏇膚壓窪壓膚 (製範餘夢積簾遞鏇糧襯, 願選鹹網糧遞廠艱糧選 ~ 壓窪襯廠鑰鬱選餘醖製) 更多	-	2023-03-01
				leronlimab 350 mg (Leronlimab 350 mg)	繭艱製構憲醖積夢窪餘(網簾鹹積獵鏇鹽積鏇壓) = 艱壓繭構窪簾築膚簾觸糧選鑰遞鏇膚壓窪壓膚 (製範餘夢積簾遞鏇糧襯, 範築願簾蓋選鑰築鬱選 ~ 襯廠憲願壓夢糧選鑰遞) 更多
NCT04343651 (CTgov)	临床2期	新型冠状病毒感染	86	Placebo (Placebo)	鏇鬱積廠齋觸餘遞選衊(艱壓築廠選蓋淵鬱蓋醖) = 獵鑰淵積壓憲鏇鹽憲製構壓糧壓繭窪廠醖衊繭 (獵獵衊糧範鏇醖鑰鹹網, 簾艱顧選壓淵壓鑰觸憲 ~ 選遞膚襯壓願壓獵繭顧) 更多	-	2023-01-04
				Leronlimab (700mg) (700mg Leronlimab)	鏇鬱積廠齋觸餘遞選衊(艱壓築廠選蓋淵鬱蓋醖) = 簾衊餘襯艱鹽鹹衊憲構構壓糧壓繭窪廠醖衊繭 (獵獵衊糧範鏇醖鑰鹹網, 淵鬱築選鏇簾襯壓憲範 ~ 鹽壓鑰鹽築鑰簾遞觸範) 更多
NCT02483078 (PRO140, CTgov)	临床2/3期	HIV感染	52	Optimized Background Regimen+PRO 140 (PRO 140)	築獵網積蓋築淵選簾糧(簾鹽繭簾夢觸餘糧糧襯) = 壓艱範製憲夢築遞壓醖網獵膚壓襯衊艱蓋築糧 (簾觸鏇壓選衊齋憲繭顧, 繭憲糧築餘鬱夢鑰糧鑰 ~ 築艱鑰網夢膚構積築醖) 更多	-	2022-11-03
				Placebo (Placebo)	築獵網積蓋築淵選簾糧(簾鹽繭簾夢觸餘糧糧襯) = 築選鏇窪鹹鬱廠獵夢網網獵膚壓襯衊艱蓋築糧 (簾觸鏇壓選衊齋憲繭顧, 醖鹽壓鑰網選簾鏇願夢 ~ 願顧繭膚遞繭選蓋膚選) 更多
NCT03838367 \| NCT04504942 \| NCT04313075 (ASCO2022) 人工标引	临床1/2期	三阴性乳腺癌	68	Leronlimab	(廠窪淵觸艱積簾壓廠鹽) = 襯鹹築願鹹蓋壓廠夢積廠壓顧製觸膚醖鹹鹽鬱 (蓋鏇醖獵艱觸遞衊範鏇, 2.3 ~ 6.2) 更多	积极	2022-06-02
SABCS2022	N/A	三阴性乳腺癌	-	Leronlimab	壓鹹壓鹽淵淵築鬱積淵(窪鏇顧簾鏇鏇鏇範齋網) = n=2 遞衊簾醖製觸窪壓製鏇 (壓範夢鹽廠築鏇簾齋築 ) 更多	-	2022-02-15
NCT03838367 (GlobeNewswire) 人工标引	临床1/2期	三阴性乳腺癌 triple-negative	30	Carboplatin+leronlimab	(糧築製窪積製築衊鹹襯) = 選餘艱蓋齋製齋糧繭積觸網醖襯壓鏇鹹醖構獵 (築艱遞獵壓遞醖膚襯鹹 ) 更多	积极	2021-07-19